Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. …

Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.

Apr 8, 2025 · Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and …

Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine.

The Investor Relations website contains information about Sarepta Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases. Today, our primary focus is on Duchenne muscular dystrophy, …

Sarepta is at the forefront of precision genetic medicine, with over 40 therapies in various stages of development. Our disease areas include Duchenne muscular dystrophy (DMD), six Limb …

Call 1-888-SAREPTA (1-888-727-3782) Available Monday through Friday, 8:30am - 6:30pm ET. Spanish-speaking Case Managers and interpreters for other languages are available.

Sarepta currently has multiple clinical trials for Duchenne underway in both gene therapy and RNA exon-skipping.

Feb 26, 2025 · Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments 02/26/25 4:05 PM EST – Net product revenues …